Investigational New Drugs

Papers
(The H4-Index of Investigational New Drugs is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Clinical features, treatment and outcomes of dabrafenib-associated uveitis44
Direct functional HOXA9/DNA-binding competitors versus epigenetic inhibitors of HOXA9 expression on cell proliferation, death and differentiation processes in the model of MLL-rearranged acute myeloid44
Gefitinib, an effective treatment option for patients with pulmonary enteric adenocarcinoma harboring compound EGFR L858R and A871G mutation42
The ATR inhibitor berzosertib acts as a radio- and chemosensitizer in head and neck squamous cell carcinoma cell lines41
MLN0905, a new inhibitor of Polo-like kinase 1 (PLK1), enhances the efficiency of lenalidomide in promoting the apoptosis of multiple myeloma cell lines36
Enhanced antitumor and anti-metastasis by VEGFR2-targeted doxorubicin immunoliposome synergy with NK cell activation35
Improved delivery of Mcl-1 and survivin siRNA combination in breast cancer cells with additive siRNA complexes34
Neoadjuvant immunochemotherapy in locally advanced laryngeal cancer and hypopharyngeal cancer: higher objective response rate and organ-preservation rate32
Idarubicin versus epirubicin in drug-eluting beads-transarterial chemoembolization for treating hepatocellular carcinoma: A real-world retrospective study30
Safety and efficacy of apatinib in combination with chemotherapy with or without immunotherapy versus chemotherapy alone as first-line treatment for advanced gastric cancer29
IL-10 contributes to gemcitabine resistance in extranodal NK/T-cell lymphoma cells via ABCC428
RNA silencing of GM-CSF in CAR-T cells reduces the secretion of multiple inflammatory cytokines25
Research progress on cancer-related epigenetic switches25
The kinesin Eg5 inhibitor K858 exerts antiproliferative and proapoptotic effects and attenuates the invasive potential of head and neck squamous carcinoma cells25
Synergistic antitumor effect of MK-1775 and CUDC-907 against prostate cancer24
The analysis of molecular classification of pulmonary neuroendocrine tumors and relationship between YAP1 and efficacy22
A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case report21
A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [14C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healt21
Palladium(II) Schiff base complex arrests cell cycle at early stages, induces apoptosis, and reduces Ehrlich solid tumor burden: a new candidate for tumor therapy21
Phase II trial of multi-kinase inhibitor ESK981 in patients with metastatic castration-resistant prostate cancer21
A phase I/II study of LY3022855 with BRAF/MEK inhibition in patients with Melanoma20
5-Fluorouracil-methotrexate conjugate enhances the efficacy of 5-fluorouracil in colorectal cancer therapy20
The role of dinutuximab beta with beta cell function, apoptosis, and proliferation: new approaches to proteomic analysis of insulinoma20
Efficacy of salvage therapies after failure of adjuvant anti-PD-1 monotherapy for melanoma in the Chinese population: a multi-institutional cohort study20
0.037941217422485